Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria.
Syreon Research Institute, Budapest, Hungary.
Front Public Health. 2022 Jul 14;10:921226. doi: 10.3389/fpubh.2022.921226. eCollection 2022.
The aim of this paper is to identify the barriers that are specifically relevant to the use of Artificial Intelligence (AI)-based evidence in Central and Eastern European (CEE) Health Technology Assessment (HTA) systems. The study relied on two main parallel sources to identify barriers to use AI methodologies in HTA in CEE, including a scoping literature review and iterative focus group meetings with HTx team members. Most of the other selected articles discussed AI from a clinical perspective ( = 25), and the rest are from regulatory perspective ( = 13), and transfer of knowledge point of view ( = 3). Clinical areas studied are quite diverse-from pediatric, diabetes, diagnostic radiology, gynecology, oncology, surgery, psychiatry, cardiology, infection diseases, and oncology. Out of all 38 articles, 25 (66%) describe the AI method and the rest are more focused on the utilization barriers of different health care services and programs. The potential barriers could be classified as data related, methodological, technological, regulatory and policy related, and human factor related. Some of the barriers are quite similar, especially concerning the technologies. Studies focusing on the AI usage for HTA decision making are scarce. AI and augmented decision making tools are a novel science, and we are in the process of adapting it to existing needs. HTA as a process requires multiple steps, multiple evaluations which rely on heterogenous data. Therefore, the observed range of barriers come as a no surprise, and experts in the field need to give their opinion on the most important barriers in order to develop recommendations to overcome them and to disseminate the practical application of these tools.
本文旨在确定在中东欧(CEE)卫生技术评估(HTA)系统中使用人工智能(AI)证据时特别相关的障碍。该研究依赖于两个主要的平行来源来确定在 CEE 的 HTA 中使用 AI 方法的障碍,包括范围广泛的文献综述和与 HTx 团队成员进行的迭代焦点小组会议。其他选定的文章大多从临床角度讨论 AI(=25 篇),其余的来自监管角度(=13 篇)和知识转移角度(=3 篇)。研究的临床领域非常多样化,包括儿科、糖尿病、诊断放射学、妇科、肿瘤学、外科、精神病学、心脏病学、传染病和肿瘤学。在所有 38 篇文章中,有 25 篇(66%)描述了 AI 方法,其余的则更侧重于不同医疗保健服务和项目的利用障碍。潜在的障碍可以分为数据相关、方法学、技术、监管和政策相关以及人为因素相关。有些障碍非常相似,尤其是在技术方面。专注于 AI 在 HTA 决策中的使用的研究很少。AI 和增强决策工具是一门新兴科学,我们正在将其应用于现有需求的过程中。HTA 作为一个过程需要多个步骤,多个评估,这些评估依赖于异质数据。因此,观察到的一系列障碍并不奇怪,该领域的专家需要就最重要的障碍发表意见,以便制定克服这些障碍的建议,并传播这些工具的实际应用。